



ITW

PTO/SB/21 (09-04)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/662906-Conf. #1268
	Filing Date	September 15, 2003
	First Named Inventor	Rong-Hwa Lin
	Art Unit	1644
	Examiner Name	P. Gambel
Total Number of Pages in This Submission	Attorney Docket Number	A0871.70001US00

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement/PTO Form 1449 with references <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Receipt Postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	WOLF, GREENFIELD & SACKS, P.C.		
Signature			
Printed name	Alan W. Steele, M.D., Ph.D.		
Date	August 1, 2006	Reg. No.	45,128

Certificate of Mailing Under 37 CFR 1.8(a)	
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Dated: <u>August 2006</u>	Signature: <u></u> (Alan W. Steele, M.D., Ph.D.)



DOCKET NO.: A0871.70001US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Rong-Hwa Lin et al.  
Serial No.: 10/662,906  
Confirmation No.: 1268  
Filed: September 15, 2003  
For: MODULATORS OF P-SELECTIN GLYCOPROTEIN  
LIGAND 1

Examiner: Phillip Gambel  
Art Unit: 1644

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 1st day of August, 2006.

Alan W. Steele, M.D., Ph.D., Reg. No. 45,128

---

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF  
DISCLOSURE UNDER 37 C.F.R. §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement is being filed before the mailing of a first Office action on the merits in the above-identified case.

No fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

The Applicant would like to bring to the Examiner's attention the following co-pending applications that may contain subject matter related to this application:

<u>Serial No.</u>	<u>Filing Date</u>	<u>Inventor(s)</u>	<u>Attorney Docket No.</u>
10/051,497	01/18/2002	Rong-Hwa Lin et al.	A0871.70000US01
11/125,837	05/10/2005	Rong-Hwa Lin et al.	A0871.70002US01
11/127,804	05/11/2005	Rong-Hwa Lin et al.	A0871.70003US02

The Applicant would like to bring to the Examiner's attention the enclosed search report from corresponding International Application No. PCT/US04/29520.

The Applicant would like to bring to the Examiner's attention the enclosed search report from related International Application No. PCT/US02/07498.

The Applicant would like to bring to the Examiner's attention the enclosed search report from related European Application No. EP 02733839.1.

### PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.


Respectfully submitted,

By:



Alan W. Steele, M.D., Ph.D.  
Reg. No. 45,128  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210-2206  
Telephone: (617) 646-8000

Docket No.: A0871.70001US00  
Date: August 1, 2006  
**xNDDx**

FORM PTO-1449/A and B (modified PTO/SB/08) <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> 				APPLICATION NO.: 10/662,906	ATTY. DOCKET NO.: A0871.70001US00
				FILING DATE: September 15, 2003	CONFIRMATION NO.: 1268
				APPLICANT: Rong-Hwa Lin et al.	
				GROUP ART UNIT: 1644	EXAMINER: Phillip Gambel
Sheet	1	of	4		

#### U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A1	5,378,464		McEver	01-03-1995
	A2	5,618,785		Heavner et al.	04-08-1997
	A3	5,709,859		Aruffo et al.	01-20-1998
	A4	5,710,123		Heavner et al.	01-20-1998
	A5	5,808,025		Tedder et al.	09-15-1998
	A6	5,827,817		Larsen et al.	10-27-1998
	A7	5,834,425		Tedder et al.	11-10-1998
	A8	5,840,679		Larsen et al.	11-24-1998
	A9	5,843,707		Larsen et al.	12-01-1998
	A10	5,852,175		Cummings et al.	12-22-1998
	A11	5,972,625		Rosen et al.	10-26-1999
	A12	6,056,956		Cobbold et al.	05-02-2000
	A13	6,124,267		McEver et al.	09-26-2000
	A14	6,309,639		Cummings et al.	10-30-2001
	A15	2002-0164336	A1	Harrison et al.	11-07-2002
	A16	6,667,036		Cummings et al.	12-23-2003

#### FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
	*B1	WO	97/06176		Board of Regents of Univ. of Oklahoma	02-20-1997	
	*B2	WO	00/25808	A1	Genetics Institute, Inc.	05-11-2000	
	B3	WO	03/013603	A1	AbGenomics Corp.	02-20-2003	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/051,497, filed 01/18/2002, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

FORM PTO-1449/A and B (modified PTO/SB/08)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/662,906	ATTY. DOCKET NO.: A0871.70001US00
				FILING DATE: September 15, 2003	CONFIRMATION NO.: 1268
				APPLICANT: Rong-Hwa Lin et al.	
				GROUP ART UNIT: 1644	EXAMINER: Phillip Gambel
Sheet	2	of	4		

**OTHER ART — NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	*C1	BATTISTINI, et al. "CD8+ T cells from 1-37 patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: A critical role for P-selectin glycoprotein ligand-1." <i>Blood</i> , Vol. 101, No. 12, 4775-4782 (June 15, 2003).	
	*C2	BECKWITH et al., "The Protein Product of the Proto-oncogene c-cbl Forms a Complex With Phosphatidylinositol 3-Kinase p85 and CID 19 in Anti-IgM Stimulated Human B-Lymphoma Cells," <i>Blood</i> 88(9):3502-3507, (1996).	
	*C3	BESNAULT et al., "B Cell Receptor Cross-Linking Triggers a Caspase-8-Dependent Apoptotic Pathway That Is Independent of the Death Effector Domain of Fas-Associated Death Domain Protein," <i>J. Immunol.</i> , 167:733-740, (2001).	
	*C4	BORGES et al., "P-Selectin Glycoprotein Ligand-1 (PSGL-1) on T Helper 1 but Not on T Helper 2 Cells Binds to P-Selectin and Supports Migration into Inflamed Skin," <i>J. Exp. Med.</i> 185(3):573-578 (February 3, 1997).	
	*C5	BORGES et al., "The Binding of T Cell-expressed P-selectin Glycoprotein Ligand-1 to E- and P-selectin Is Differentially Regulated," <i>J. Biol. Chem.</i> 272(45):28786-28792 (November 7, 1997).	
	*C6	DIACOVO, et al. "Interactions of human alpha/beta and gamma/delta T lymphocyte subsets in shear flow with E-selectin and P-selectin." <i>J. Exp. Med.</i> , Vol. 183, 1193-1203 (March 1996).	
	*C7	DIMITROFF, et al. "Glycosylation-dependent inhibition of cutaneous lymphocyte-associated antigen expression: Implications in modulating lymphocyte migration to skin." <i>Blood</i> , Vol. 101, No. 2, 602-610 (January 15, 2003).	
	*C8	EVANGELISTA et al., "Platelet/Polymorphonuclear Leukocyte Interaction: P-Selectin Triggers Protein-Tyrosine Phosphorylation-Dependent CD11b/CD 18 Adhesion: Role of PSGL-1 as a Signaling Molecule," <i>Blood</i> 93(3):876-885 (February 1, 1999).	
	*C9	FARADAY et al., "Leukocytes Can Enhance Platelet-mediated Aggregation and Thromboxane Release via Interaction of P-selectin Glycoprotein Ligand 1 with P-selectin," <i>Anesthesiology</i> 94(1):145-151 (January 2001).	
	*C10	FRENETTE et al., "P-Selectin Glycoprotein Ligand 1 (PSGL-1) Is Expressed on Platelets and Can Mediate Platelet-Endothelial Interactions In Vivo," <i>J. Exp. Med.</i> 191(8):1413-1422 (April 17, 2000).	
	*C11	FUHLBRIGGE et al., "Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells," <i>Nature</i> 389:978-981 (October 1997).	
	C12	HERRON MJ et al., Intracellular parasitism by the human granulocytic ehrlichiosis bacterium through the P-selectin ligand, PSGL-1. <i>Science</i> . 2000 Jun 2;288(5471):1653-6.	
	*C13	HIRATA et al., "P-Selectin Glycoprotein Ligand 1 (PSGL-1) Is a Physiological Ligand for E-Selectin in Mediating T Helper 1 Lymphocyte Migration," <i>J. Exp. Med.</i> 192(11):1669-1675 (December 4, 2000).	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/051,497, filed 01/18/2002, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

FORM PTO-1449/A and B (modified PTO/SB/08)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/662,906	ATTY. DOCKET NO.: A0871.70001US00
				FILING DATE: September 15, 2003	CONFIRMATION NO.: 1268
				APPLICANT: Rong-Hwa Lin et al.	
				GROUP ART UNIT: 1644	EXAMINER: Phillip Gambel
Sheet	3	of	4		

	*C14	HIROSE et al., "A functional epitope on P-selectin that supports binding of P-selectin to P-selectin glycoprotein ligand-1 but not to sialyl Lewis X oligosaccharides," <i>Internatl. Immunol.</i> 10(5):639-649 (January 26, 1998).	
	*C15	IGARASHI et al., "Telomerase Activity Is Induced in Human Peripheral B Lymphocytes by the Stimulation to Antigen Receptor," <i>Blood</i> , 89(4):1299-1307, (1997).	
	*C16	KAYTES, et al. "P-selectin mediates 1-37 adhesion of the human melanoma cell line NKI-4: Identification of glycoprotein ligands." <i>Biochemistry</i> , Vol. 37, No. 29, 10514-10521 (July 21, 1998).	
	*C17	KIEFFER, et al. "Neutrophils, monocytes, and dendritic cells express the same specialized form of PSGL-1 as do skin-homing memory T cells: Cutaneous lymphocyte antigen." <i>Biochem. Biophys. Res. Comm.</i> , Vol. 285, No. 3, 577-587 (July 20, 2001).	
	*C18	LASZIK et al., "P-Selectin Glycoprotein Ligand-1 Is Broadly Expressed in Cells of Myeloid, Lymphoid, and Dendritic Lineage and in Some Nonhematopoietic Cells," <i>Blood</i> 88(8):3010-3021 (October 15, 1996).	
	*C19	LEVESQUE et al., "PSGL-1-Mediated Adhesion of Human Hematopoietic Progenitors to P-Selectin Results in Suppression of Hematopoiesis," <i>Immunity</i> 11:369-378 (September, 1999).	
	C20	LI et al., "Visualization of P-Selectin Glycoprotein Ligand-1 As A Highly Extended Molecule and Mapping of Protein Epitopes for Monoclonal Antibodies," <i>J. Biol.Chem.</i> 271(11):6342-6348 (1996).	
	C21	MOORE et al., "P-Selectin Glycoprotein Ligand-1 Mediates Rolling of Human Neutrophils on P-Selectin," <i>J. Cell Biol.</i> 128(4):661-671 (1995).	
	C22	SAKO D et al., Expression cloning of a functional glycoprotein ligand for P-selectin. <i>Cell</i> . 1993 Dec 17;75(6):1179-86.	
	*C23	SHAN et al., "Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies," <i>Blood</i> , 91(5):1644-1652, (1998)	
	*C24	SNAPP et al., "A Novel P-Selectin Glycoprotein Ligand-1 Monoclonal Antibody Recognizes an Epitope Within the Tyrosine Sulfate Motif of Human PSGL-1 and Blocks Recognition of Both P- and L-Selectin," <i>Blood</i> 91(1):154-164 (January 1, 1998).	
	*C25	STOCKMEYER et al., "Polymorphonuclear Granulocytes Induce Antibody-Dependent Apoptosis in Human Breast Cancer Cells," <i>J. Immunol.</i> , 171:5124-5129, (2003).	
	C26	TREMBLEAU, et al., "Pancreas-Infiltrating Th1 Cells and Diabetes Develop in IL-12 Deficient Nonobese Diabetic Mice," <i>J. Immunol.</i> 163:2960-2968 1999).	
	C27	VACHINO G et al., P-selectin glycoprotein ligand-1 is the major counter-receptor for P-selectin on stimulated T cells and is widely distributed in non-functional form on many lymphocytic cells. <i>J Biol Chem.</i> 1995 Sep 15;270(37):21966-74.	
	C28	VELDMAN GM et al., Genomic organization and chromosomal localization of the gene encoding human P-selectin glycoprotein ligand. <i>J Biol Chem.</i> 1995 Jul 7;270(27):16470-5.	
	*C29	WING et al., "Mechanism of First-Dose Cytokine-Release Syndrome by CAMPATH 1-H: Involvement of CD16 (FcγRIII) and CD11a/CD18 (LFA-1) on NK Cells," <i>J. Clin. Invest.</i> 98(12):2819-2826 (1996).	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/051,497, filed 01/18/2002, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

FORM PTO-1449/A and B (modified PTO/SB/08)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		APPLICATION NO.: 10/662,906	ATTY. DOCKET NO.: A0871.70001US00
		FILING DATE: September 15, 2003	CONFIRMATION NO.: 1268
		APPLICANT: Rong-Hwa Lin et al.	
		GROUP ART UNIT: 1644	EXAMINER: Phillip Gambel
Sheet	4	of	4

	*C30	WOLTMANN, et al. "Interleukin-13 induces PSGL-1/P-selectin-dependent adhesion of eosinophils, but not neutrophils, to human umbilical vein endothelial cells under flow." <i>Blood</i> , Vol. 95, No. 10, 3146-3152 (May15, 2000).	
	C31	WU et al., "Role of P-Selectin and Anti-P-Selectin Monoclonal Antibody in Apoptosis During Hepatic/Renal Ischemia Reperfusion Injury," <i>World J. Gastroentero</i> 6(2):244-247 (2000).	
	C32	YAGO et al., "IL-12 Promotes the Adhesion of NK Cells to Endothelial Selectins Under Flow Conditions," <i>J. Immunol.</i> 161:1140-1145 (1998).	
	*C33	YANG et al., "Targeted Gene Disruption Demonstrates That P-Selectin Glycoprotein Ligand 1 (PSGL-1) Is Required for P-Selectin-mediated but Not E-Selectin-mediated Neutrophil Rolling and Migration," <i>J. Exp. Med.</i> 190(12):1769-1782 (December 20, 1999).	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/051,497, filed 01/18/2002, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]